Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
Several other equities research analysts have also recently weighed in on PRTK. HC Wainwright cut shares of Paratek Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, June 7th. Jefferies Financial Group lowered shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 7th. Finally, BTIG Research reduced their price objective on Paratek Pharmaceuticals from $24.00 to $5.00 in a report on Tuesday, May 9th.
Paratek Pharmaceuticals Price Performance
NASDAQ PRTK opened at $2.19 on Wednesday. The stock’s 50 day simple moving average is $2.02 and its 200 day simple moving average is $2.00. Paratek Pharmaceuticals has a one year low of $1.29 and a one year high of $3.65. The firm has a market cap of $125.44 million, a PE ratio of -1.86 and a beta of 1.59.
Insider Buying and Selling at Paratek Pharmaceuticals
In other Paratek Pharmaceuticals news, major shareholder James D. Dondero bought 106,000 shares of the stock in a transaction on Wednesday, March 22nd. The stock was purchased at an average price of $1.77 per share, with a total value of $187,620.00. Following the acquisition, the insider now owns 2,056,000 shares of the company’s stock, valued at $3,639,120. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In other news, major shareholder James D. Dondero acquired 105,137 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, March 20th. The shares were acquired at an average price of $1.40 per share, with a total value of $147,191.80. Following the purchase, the insider now directly owns 2,239,770 shares of the company’s stock, valued at $3,135,678. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder James D. Dondero bought 106,000 shares of the stock in a transaction on Wednesday, March 22nd. The stock was purchased at an average cost of $1.77 per share, with a total value of $187,620.00. Following the purchase, the insider now directly owns 2,056,000 shares of the company’s stock, valued at approximately $3,639,120. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 446,000 shares of company stock worth $687,106. Company insiders own 8.00% of the company’s stock.
Hedge Funds Weigh In On Paratek Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in PRTK. AIGH Capital Management LLC lifted its stake in Paratek Pharmaceuticals by 6.9% in the fourth quarter. AIGH Capital Management LLC now owns 4,156,891 shares of the specialty pharmaceutical company’s stock valued at $7,773,000 after buying an additional 269,719 shares in the last quarter. Vanguard Group Inc. increased its holdings in Paratek Pharmaceuticals by 5.4% during the 1st quarter. Vanguard Group Inc. now owns 2,278,878 shares of the specialty pharmaceutical company’s stock worth $6,768,000 after purchasing an additional 117,105 shares in the last quarter. General American Investors Co. Inc. lifted its holdings in shares of Paratek Pharmaceuticals by 1.6% in the first quarter. General American Investors Co. Inc. now owns 1,914,424 shares of the specialty pharmaceutical company’s stock valued at $4,863,000 after purchasing an additional 30,031 shares in the last quarter. BlackRock Inc. boosted its position in shares of Paratek Pharmaceuticals by 38.5% during the third quarter. BlackRock Inc. now owns 1,203,446 shares of the specialty pharmaceutical company’s stock worth $3,092,000 after buying an additional 334,222 shares during the period. Finally, Carlyle Group Inc. acquired a new stake in Paratek Pharmaceuticals in the 1st quarter valued at approximately $2,624,000. Institutional investors and hedge funds own 41.90% of the company’s stock.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections.
Featured Stories
- Get a free copy of the StockNews.com research report on Paratek Pharmaceuticals (PRTK)
- As Peloton Shares Fall Over 90%, A Comeback Strategy Surges
- Inflation, The Fed, And The Summer Rally
- How to Trade Stocks Online the Right Way
- SentinelOne Stock is Down, But Is it Out?
- Oracle Has Spoken: The AI Cloud Is Bigger And Growing Faster
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
